Scientific Evidence

An Automated Tissue Systems Pathology Test Can Standardize the Management and Improve Health Outcomes for Patients With Barrett's Esophagus

Nov 2023

Management guided by the TSP-9 test can standardize care plans by increasing the early detection of progressors who can receive therapeutic interventions, while also increasing the percentage of nonprogressors who can avoid unnecessary therapy and be managed by surveillance alone.

Author: Duitas, Lucas C, et al.

Publication: American Journal of Gastroenterology

A Tissue Systems Pathology Test Enables Risk-Aligned Management of Patients With Non-Dysplastic Barrett’s Esophagus: Case Reports From a Gastrointestinal Surgery Center

Sep 2023

TissueCypher demonstrated clinical utility in NDBE patients by guiding risk-aligned upstaging of care and potential improved health outcomes in BE patients.

Author: Tseng D, et al.

Publication: Foregut: The Journal of the American Foregut Society

The tissue systems pathology-9 test provides clinically-impactful risk stratification in patients with Barrett’s esophagus: clinical experience in a multicenter cohort

Aug 2023

This study evaluated the use of the validated, commercially-available tissue systems pathology test (TissueCypher, TSP-9) to risk-stratify BE patients in a large clinical practice cohort.

Author: Villa NA, et al.

Publication: Diseases of the Esophagus

The Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients With Low-Grade Dysplasia

Aug 2023

This study aimed to compare the risk stratification performance of the TSP-9 test vs benchmarks of generalist and expert pathology.

Author: Khoshiwal AM, Frei NF, et al.

Publication: Gastroenterology

A Tissue Systems Pathology Test Outperforms the Standard of Care Variables in Predicting Progression in Patients with Barrett’s Esophagus

Aug 2023

This study evaluated the predictive performance of a tissue systems pathology test (TissueCypher, TSP-9) versus current clinicopathologic variables in a multi-center cohort of BE patients.

Author: Davison JM, et al.

Publication: Clinical and Translational Gastroenterology

Tissue systems pathology test objectively risk stratifies Barrett’s esophagus patients with low grade dysplasia

Apr 2023

The risk prediction assay provided significant risk stratification in BE patients with LGD and identified progressors that the experts downstaged to NDBE.

Author: Frei NF, et al.

Publication: American Journal of Gastroenterology

Spatialomics delivered to the clinic for improved health outcomes in Barrett’s esophagus

Dec 2022

The spatialomics approach of TissueCypher brings precision pathology to the clinic for more personalized care of patients with BE to improve outcomes.

Author: Munroe C, et al.

Publication: The Journal of Precision Medicine

Independent validation of TissueCypher to predict progression in community-based Barrett’s esophagus with low grade dysplasia: analysis in a completed prospective study (podium presentation at UEG 2020 annual meeting OP017)

Oct 2022

TissueCypher may be a practical and effective solution to the lack of standardization of expert pathology review of LGD as advocated by all guidelines.

Author: Frei NF, et al.

Publication: United European Gastroenterology Journal

An objective spatialomics test standardizes management decisions with potential to improve outcomes for Barrett’s esophagus patients (podium presentation at ACG 2022, Charlotte S386)

Oct 2022

This study evaluated the impact that variability in pathologic diagnosis has on patient care and shows how TissueCypher can aid in consistency of BE management.

Author: Frei NF, et al.

Publication: American Journal of Gastroenterology

An objective fully automated Barrett’s risk prediction assay outperforms most pathologists in risk stratifying Barrett’s esophagus with low grade dysplasia (podium presentation at DDW 2022, San Diego 695)

May 2022

Conventional pathology review based on histology has limitations, and the TissueCypher BE risk assessment tool can improve the accuracy of prognosis.

Author: Khoshiwal AM, et al.

Publication: Endoscopy

An objective fully-automated Barrett's risk prediction assay outperforms most pathologists in risk stratifying Barrett's esophagus with low-grade dysplasia (podium presentation at ESGE 2022, Prague OP079)

Apr 2022

Histological review of community-based LGD showed a high inter-observer variability with a signification number of cases classified as non-informative.

Author: Khoshiwal A, et al.

Publication: Endoscopy

Prediction of progression in Barrett’s esophagus using a tissue systems pathology test: a pooled analysis of international multicenter studies

Feb 2022

Across all analyses, TissueCypher was the strongest and most significant predictor of progression to HGD or EAC.

Author: Iyer PG, et al.

Publication: Clinical Gastroenterology and Hepatology